DDInter655 DDInter1658
An anthracycline which is the 4&#39;-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Epirubicin {u} (Compound) resembles {v} (Compound) Doxorubicin
Epirubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Epirubicin {u} (Compound) treats {v} (Disease) ovarian cancer
Epirubicin {u} (Compound) binds {v} (Gene) YWHAG
Epirubicin {u} (Compound) upregulates {v} (Gene) SCPEP1
Epirubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Epirubicin {u} (Compound) downregulates {v} (Gene) KPNA2
Epirubicin {u} (Compound) causes {v} (Side Effect) Haemoptysis
Epirubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aldesleukin
Epirubicin (Compound) resembles Doxorubicin (Compound)
Epirubicin (Compound) resembles Valrubicin (Compound)
Epirubicin (Compound) treats ovarian cancer (Disease)
Epirubicin (Compound) binds YWHAG (Gene)
Epirubicin (Compound) upregulates SCPEP1 (Gene)
Epirubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Epirubicin (Compound) downregulates KPNA2 (Gene)
Epirubicin (Compound) causes Haemoptysis (Side Effect)
Epirubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin